Improving Access to Trikafta for Cystic Fibrosis Patients in South Africa

By João L. Carapinha

December 16, 2024

The Competition Commission of South Africa recently published a media statement on cystic fibrosis medication access – Trikafta. This article highlights improvements in access to Trikafta, a critical medication for cystic fibrosis patients. Access to Trikafta has been primarily enhanced through the mechanisms established by Vertex Pharmaceuticals which has passed a review by the Competition Commission of South Africa.

Section 21 of the Medicines and Related Substances Act

– Section 21 allows SAHPRA to authorize the sale of unregistered medicines in South Africa under certain conditions. This provision enables registered medical practitioners to apply for approval to use unregistered medicines, such as Trikafta, for individual patients.
– In the context of Trikafta, Vertex has committed to making this medication available through Section 21. This approach allows patients in South Africa to access Trikafta even if it is not fully registered with SAHPRA.

Patient Access Program and Financial Assistance

– Vertex launched a patient assistance program, managed by an NGO, to reduce financial burdens on eligible patients. This initiative ensures that some cystic fibrosis patients can access Trikafta at no cost.
– Eligible patients under specific medical schemes can access Trikafta for free through financial assistance. This includes support from top-end medical plans offered by Discovery Health.

Impact on Access to Medicine Initiatives

– The decision by the Competition Commission to accept Vertex’s undertakings and non-refer the complaint is viewed as a positive outcome for access to medicine initiatives in South Africa. It guarantees that patients can access life-changing medications like Trikafta locally, at a more affordable price than before.
– The local distribution of Trikafta, starting in April 2024, significantly enhances the medication’s accessibility. Patients will no longer have to import it from other countries, aligning with public interest and the objectives of the Competition Act.

Conclusion

Overall, the initiatives undertaken by Vertex, reviewed by the Competition Commission, represent a marked improvement in access to Trikafta for cystic fibrosis patients in South Africa. The implementation of Section 21 authorizations and patient assistance programs makes this critical medication more accessible and affordable, which is a positive advancement for access to medicine initiatives in the country.

Reference url

Recent Posts

Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for IgA Nephropathy

By João L. Carapinha

October 21, 2025

Novartis has announced positive final results from the Phase III APPLAUSE-IgAN trial, which demonstrated that Fabhalta kidney treatment (iptacopan) achieved a statistically significant and clinically meaningful slowing of kidney function decline in patients with IgA nephropathy compared to placeb...
Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk Groups

By HEOR Staff Writer

October 17, 2025

Cabotegravir HIV prevention is now officially recommended in the UK for adults and young people at high risk of HIV who cannot take daily oral PrEP. What makes this approval so significant? For those unable to adhere to daily medication, cabotegravir provides a bi-monthly injectable alternative w...
Social Media Policy Action: Protecting Youth from Cognitive Risks

By João L. Carapinha

October 16, 2025

A recent editorial published in JAMA emphasizes the urgent need for social media policy action due to the developmental impacts of social media on youth. The article discusses a pivotal study by Nagata et al., which examined a large cohort of adolescents. This study revealed that increas...